{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T17:48:25Z","timestamp":1782755305773,"version":"3.54.5"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T00:00:00Z","timestamp":1505865600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P20CA192987"],"award-info":[{"award-number":["P20CA192987"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0185111","type":"journal-article","created":{"date-parts":[[2017,9,20]],"date-time":"2017-09-20T17:36:35Z","timestamp":1505928995000},"page":"e0185111","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines"],"prefix":"10.1371","volume":"12","author":[{"given":"Vijayalakshmi N.","family":"Ayyagari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula L.","family":"Diaz-Sylvester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-han Jeff","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2017,9,20]]},"reference":[{"issue":"2","key":"ref1","first-page":"115","article-title":"[The mechanism of cisplatin-resistance in ovarian cancer]","volume":"14","author":"Y Kikuchi","year":"2001","journal-title":"Hum Cell"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0090-8258(03)00464-5","article-title":"Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy","volume":"91","author":"MM Leitao","year":"2003","journal-title":"Gynecol Oncol"},{"issue":"5","key":"ref3","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1111\/j.1048-891X.2004.014507.x","article-title":"Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population","volume":"14","author":"HE Lambert","year":"2004","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/ardp.200600151","article-title":"Non platinum metal complexes as anti-cancer drugs","volume":"340","author":"I Ott","year":"2007","journal-title":"Arch Pharm (Weinheim)"},{"issue":"15","key":"ref5","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","article-title":"Paclitaxel (taxol)","volume":"332","author":"EK Rowinsky","year":"1995","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/0165-6147(92)90048-B","article-title":"Mechanism of action of taxol","volume":"13","author":"S Band Horwitz","journal-title":"Trends in Pharmacological Sciences"},{"issue":"5","key":"ref7","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/BF03401588","article-title":"Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway","volume":"1","author":"CM Woods","year":"1995","journal-title":"Mol Med"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1757-2215-4-21","article-title":"Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin","volume":"4","author":"CA Sherman-Baust","year":"2011","journal-title":"J Ovarian Res"},{"issue":"7","key":"ref9","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","article-title":"Ovarian cancer: strategies for overcoming resistance to chemotherapy","volume":"3","author":"R Agarwal","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"ref10","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1212\/WNL.39.3.368","article-title":"Taxol produces a predominantly sensory neuropathy","volume":"39","author":"RB Lipton","year":"1989","journal-title":"Neurology"},{"issue":"15","key":"ref11","first-page":"107","article-title":"Neurotoxicity of Taxol","author":"EK Rowinsky","year":"1993","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01999566","article-title":"Paclitaxel neurotoxicity: clinical and neurophysiological study of 23 patients","volume":"18","author":"A Pace","year":"1997","journal-title":"Ital J Neurol Sci"},{"issue":"8","key":"ref13","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.4161\/cbt.5.8.2909","article-title":"Combination of gemcitabine antagonizes antitumor activity of paclitaxel through prevention of mitotic arrest and apoptosis","volume":"5","author":"M Sui","year":"2006","journal-title":"Cancer Biol Ther"},{"issue":"9","key":"ref14","first-page":"3766","article-title":"In vitro evaluation of schedule-dependent interactions between docetaxel and doxorubicin against human breast and ovarian cancer cells","volume":"6","author":"S Zeng","year":"2000","journal-title":"Clin Cancer Res"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/hep.1840140620","article-title":"Successful treatment of acute fascioliasis with bithionol","volume":"14","author":"Y Bacq","year":"1991","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1471-2407-14-61","article-title":"Bithionol inhibits ovarian cancer cell growth in vitro\u2014studies on mechanism(s) of action","volume":"14","author":"VN Ayyagari","year":"2014","journal-title":"BMC Cancer"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1097\/CAD.0000000000000364","article-title":"Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer","volume":"27","author":"VN Ayyagari","year":"2016","journal-title":"Anticancer Drugs"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12885-016-3034-2","article-title":"Evaluation of the cytotoxicity of the Bithionol\u2014cisplatin combination in a panel of human ovarian cancer cell lines","volume":"17","author":"VN Ayyagari","year":"2017","journal-title":"BMC Cancer"},{"issue":"2","key":"ref19","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"TC Chou","year":"2010","journal-title":"Cancer Res"},{"issue":"3","key":"ref20","article-title":"Staining of suspension cells with hoechst 33258 to detect apoptosis","volume":"2006","author":"S Kasibhatla","year":"2006","journal-title":"CSH Protoc"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","article-title":"Management strategies for recurrent platinum-resistant ovarian cancer","volume":"71","author":"RW Naumann","year":"2011","journal-title":"Drugs"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/1758834010361333","article-title":"Practical considerations in ovarian cancer chemotherapy","volume":"2","author":"M Cristea","year":"2010","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"ref23","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.2000.18.6.1193","article-title":"Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group","volume":"18","author":"MJ Piccart","year":"2000","journal-title":"J Clin Oncol"},{"issue":"2","key":"ref24","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ctrv.2012.04.004","article-title":"Evolving concepts in the management of drug resistant ovarian cancer: dose dense chemotherapy and the reversal of clinical platinum resistance","volume":"39","author":"DJ Pinato","year":"2013","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"ref25","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1080\/028418602320404998","article-title":"Randomized trial of single agent paclitaxel given weekly versus every three weeks and with peroral versus intravenous steroid premedication to patients with ovarian cancer previously treated with platinum","volume":"41","author":"P Rosenberg","year":"2002","journal-title":"Acta Oncol"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1038\/nm1001-1111","article-title":"Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells","volume":"7","author":"PM Hwang","year":"2001","journal-title":"Nat Med"},{"issue":"1","key":"ref27","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ygyno.2011.03.035","article-title":"Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines","volume":"122","author":"KK Kim","year":"2011","journal-title":"Gynecol Oncol"},{"key":"ref28","unstructured":"Braddock D, inventorApplication WO2009151644 A2. Yale University, USA (2009). Small molecule inhibitors of autotaxin, and methods of use. This patent is notable as one of only two that include demonstration in vivo of anti- cancer activity of an ATX inhibitor."},{"issue":"10","key":"ref29","doi-asserted-by":"crossref","first-page":"3352","DOI":"10.1158\/1535-7163.MCT-08-0463","article-title":"Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion","volume":"7","author":"LP Saunders","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"ref30","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1084\/jem.182.2.367","article-title":"Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death","volume":"182","author":"N Zamzami","year":"1995","journal-title":"J Exp Med"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1006\/excr.2000.4838","article-title":"Induction of apoptosis by cancer chemotherapy","volume":"256","author":"SH Kaufmann","year":"2000","journal-title":"Exp Cell Res"},{"issue":"11","key":"ref32","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4","article-title":"Apoptosis in cancer: cause and cure","volume":"22","author":"SH Kaufmann","year":"2000","journal-title":"Bioessays"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3109\/1547691X.2012.655343","article-title":"Application of paclitaxel in low non-cytotoxic doses supports vaccination with melanoma antigens in normal mice","volume":"9","author":"A Sevko","year":"2012","journal-title":"J Immunotoxicol"},{"key":"ref34","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198599579.001.0001","article-title":"Guidebook to the Cytoskeletal and Motor Proteins","author":"T Kreis","year":"1999"},{"issue":"27","key":"ref35","doi-asserted-by":"crossref","first-page":"17118","DOI":"10.1074\/jbc.272.27.17118","article-title":"Paclitaxel-resistant human ovarian cancer cells have mutant beta-tubulins that exhibit impaired paclitaxel-driven polymerization","volume":"272","author":"P Giannakakou","year":"1997","journal-title":"J Biol Chem"},{"issue":"5","key":"ref36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/S0360-3016(99)00109-1","article-title":"Paclitaxel sensitivity correlates with p53 status and DNA fragmentation, but not G2\/M accumulation","volume":"44","author":"E Rakovitch","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref37","first-page":"687","article-title":"Differential Expression of Apoptosis-Associated Genes bax and bcl-2 in Ovarian Cancer","volume":"39","author":"D Marx","year":"2001","journal-title":"Methods Mol Med"},{"issue":"7","key":"ref38","first-page":"1217","article-title":"The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2","volume":"11","author":"AG Eliopoulos","year":"1995","journal-title":"Oncogene"},{"issue":"9","key":"ref39","first-page":"2178","article-title":"The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma","volume":"56","author":"JJ Herod","year":"1996","journal-title":"Cancer Res"},{"issue":"23","key":"ref40","doi-asserted-by":"crossref","first-page":"7191","DOI":"10.1158\/1078-0432.CCR-07-0362","article-title":"The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin","volume":"13","author":"J Witham","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"413076","DOI":"10.1155\/2015\/413076","article-title":"Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer","volume":"2015","author":"NC Kampan","year":"2015","journal-title":"Biomed Res Int"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1002\/ijc.23158","article-title":"Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells","volume":"122","author":"JS Kim","year":"2008","journal-title":"Int J Cancer"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1124\/mol.56.5.867","article-title":"Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin","volume":"56","author":"V Mansat-de Mas","year":"1999","journal-title":"Mol Pharmacol"},{"issue":"1","key":"ref44","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/toxsci\/kfm087","article-title":"Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion","volume":"98","author":"M Tsai-Turton","year":"2007","journal-title":"Toxicol Sci"},{"issue":"5698","key":"ref45","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/277665a0","article-title":"Promotion of microtubule assembly in vitro by taxol","volume":"277","author":"PB Schiff","year":"1979","journal-title":"Nature"},{"issue":"7","key":"ref46","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrd2803","article-title":"Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?","volume":"8","author":"D Trachootham","year":"2009","journal-title":"Nat Rev Drug Discov"},{"issue":"8","key":"ref47","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1158\/0008-5472.CAN-06-3914","article-title":"Novel action of paclitaxel against cancer cells: bystander effect mediated by reactive oxygen species","volume":"67","author":"J Alexandre","year":"2007","journal-title":"Cancer Res"},{"issue":"8","key":"ref48","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.freeradbiomed.2010.01.018","article-title":"Paclitaxel combined with inhibitors of glucose and hydroperoxide metabolism enhances breast cancer cell killing via H2O2-mediated oxidative stress","volume":"48","author":"T Hadzic","year":"2010","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"ref49","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.etp.2010.09.010","article-title":"Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells","volume":"64","author":"A Meshkini","year":"2012","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"ref50","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/ijc.22132","article-title":"Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA","volume":"120","author":"M Berndtsson","year":"2007","journal-title":"Int J Cancer"},{"issue":"3","key":"ref51","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1073\/pnas.77.3.1561","article-title":"Taxol stabilizes microtubules in mouse fibroblast cells","volume":"77","author":"PB Schiff","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref52","first-page":"279","article-title":"Paclitaxel: new uses for an old drug","volume":"8","author":"D Zhang","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"19","key":"ref53","first-page":"5390","article-title":"The phosphatidylinositol 3-kinase\/AKT signal transduction pathway plays a critical role in the expression of p21WAF1\/CIP1\/SDI1 induced by cisplatin and paclitaxel","volume":"60","author":"Y Mitsuuchi","year":"2000","journal-title":"Cancer Res"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1038\/sj.bjc.6603448","article-title":"Upregulation of p27 and its inhibition of CDK2\/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21","volume":"95","author":"G He","year":"2006","journal-title":"Br J Cancer"},{"issue":"2","key":"ref55","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/sj.onc.1203263","article-title":"Autotaxin (ATX), a potent tumor motogen, augments invasive and metastatic potential of ras-transformed cells","volume":"19","author":"SW Nam","year":"2000","journal-title":"Oncogene"},{"issue":"18","key":"ref56","first-page":"6938","article-title":"Autotaxin (NPP-2), a metastasis-enhancing motogen, is an angiogenic factor","volume":"61","author":"SW Nam","year":"2001","journal-title":"Cancer Res"},{"issue":"4","key":"ref57","article-title":"Identification of Multiple Cryptococcal Fungicidal Drug Targets by Combined Gene Dosing and Drug Affinity Responsive Target Stability Screening","volume":"7","author":"YD Park","year":"2016","journal-title":"MBio"},{"issue":"8","key":"ref58","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1093\/carcin\/16.8.1963","article-title":"Synergistic increase in chromosomal breakage within the euchromatin induced by an interaction of the benzene metabolites phenol and hydroquinone in mice","volume":"16","author":"H Chen","year":"1995","journal-title":"Carcinogenesis"},{"issue":"5665","key":"ref59","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1126\/science.1095833","article-title":"Drug delivery systems: entering the mainstream","volume":"303","author":"TM Allen","year":"2004","journal-title":"Science"},{"issue":"2","key":"ref60","doi-asserted-by":"crossref","first-page":"E128","DOI":"10.1208\/aapsj0902015","article-title":"Targeted pharmaceutical nanocarriers for cancer therapy and imaging","volume":"9","author":"VP Torchilin","year":"2007","journal-title":"AAPS J"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0185111","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T03:39:30Z","timestamp":1719459570000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0185111"}},"subtitle":[],"editor":[{"given":"Aamir","family":"Ahmad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,20]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0185111","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,20]]}}}